Lavallade et al. reported that TKIs, through the off-target inhibition of kinases such as Btk or PLC-g2, which are important for B-cell signaling, may reduce memory-B-cell frequencies in CML [31]. The gene discussed is PLCG2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.